| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Restricted stock awards granted | NaN | 0 | 0 | 257,461 |
| Net loss | -33,941,345 | -30,170,914 | -24,570,647 | -50,302,385 |
| Loss on disposal of fixed assets | NaN | 0 | -6,846 | -150,673 |
| Depreciation and amortization | 534,670 | 502,587 | 494,726 | 891,728 |
| Stock-based compensation | 5,918,055 | 3,841,360 | 3,997,348 | 9,129,091 |
| Amortization/accretion of note premiums/discounts | -358,625 | NaN | NaN | NaN |
| Changes in lease liabilities | 641,285 | 371,867 | 377,280 | -33,688 |
| Non-cash interest expense on cirm liability | NaN | 3,045,725 | NaN | NaN |
| Other | 6,591 | NaN | NaN | NaN |
| Receivables | -59,167 | 0 | -342 | -10,308,980 |
| Prepaid expenses and other assets | -979,776 | 3,325,547 | 966,329 | -198,243 |
| Accounts payable and accrued expenses | -3,081,283 | 2,168,179 | 971,647 | 2,844,166 |
| Deferred revenue | NaN | 0 | NaN | NaN |
| Net cash used in operating activities | -29,254,891 | -23,566,743 | -19,688,787 | -26,555,731 |
| Purchase of marketable securities | 174,893,062 | 14,999,760 | 58,214,848 | 78,177,790 |
| Proceeds from sales and maturities of marketable securities | 30,998,448 | 63,212,777 | 78,175,291 | 119,207,807 |
| Purchases of property and equipment | 5,121,709 | 1,664,873 | 55,843 | 1,183,745 |
| Payments for leasehold improvements | 921,752 | 0 | 8,531 | 375,008 |
| Payments for construction in progress | 4,703,521 | 3,459,884 | 3,945,048 | 1,031,264 |
| Net cash provided by (used in) investing activities | -154,641,596 | 43,088,260 | 15,951,021 | 38,440,000 |
| Net proceeds from sale of common stock | NaN | 237,033,938 | NaN | NaN |
| Proceeds from exercise of stock options | 1,470,659 | 11,781,474 | 6,950 | 69,934 |
| Net cash provided by financing activities | 1,470,659 | 248,815,412 | 6,950 | 69,934 |
| Net increase (decrease) in cash and cash equivalents | -182,425,828 | 268,336,929 | -3,730,816 | 11,954,203 |
| Cash and cash equivalents balance at beginning of period | 287,847,312 | 19,510,383 | 11,286,996 | NaN |
| Cash and cash equivalents balance at end of period | 105,421,484 | 287,847,312 | 19,510,383 | NaN |
CAPRICOR THERAPEUTICS, INC. (CAPR)
CAPRICOR THERAPEUTICS, INC. (CAPR)